title: Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.
abstract: Osteoanabolic therapy with parathyroid hormone (PTH(1-84)) or the PTH analogues teriparatide (PTH(1-34), TPTD) and abaloparatide induces a positive remodeling balance and increases modeling and remodeling activity on bone surfaces. As the anabolic action of PTH is primarily remodeling based increased bone turnover maximizes bone accrual. Increased remodeling, however, also increases cortical porosity and reduces mineralization of newly formed bone, which may cause initial reductions in BMD, particularly at sites rich in cortical bone. Increased cortical porosity may also have negative consequences for bone strength. Consequently, an interest developed in concurrent therapies offsetting the potential early negative cortical bone effects developed, and several studies using varying concurrent combinations of TPTD or PTH(1-84) with various antiresorptive (anti-catabolic) agents (estrogen, SERMs, bisphosphonates and denosumab) have been published. This commentary addresses the discrepancy between changes in areal bone mineral density (BMD) and bone turnover markers (BTM) in concurrent therapy studies leading to possible misinterpretations of the results. In studies of concurrent therapies increases in BMD are generally accompanied by decreases in biochemical markers of bone turnover. This includes Procollagen Type I N-Terminal Propetide (PINP), which has emerged as a reliable marker of bone formation during osteoanabolic therapy. We therefore want to submit, that the larger increases in BMD seen initially in patients on concurrent therapy mask the potential for later reduced osteoanabolic action of PTH. This notion is corroborated by: 1) the lesser impairment of bone anabolism seen with milder antiresorptive modalities like hormone replacement therapy (HRT) or Selective Estrogen Receptor Modulators (SERMs); 2) the changes in BMD seen in extension studies where treatment naïve patients previously treated with PTH alone are crossed over to antiresorptive drugs. We therefore advise against a general use of concurrent therapy with PTH and antiresorptive agents, as it entails blunting of osteoanabolic action of PTH in the long run.
authors.affiliation: Dept. of Clinical Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Norway.
authors.forename: Erik Fink
authors.initials: EF
authors.lastname: Eriksen
authors.affiliation: Dept. of Rheumatology, Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, Canada.
authors.forename: Jacques P
authors.initials: JP
authors.lastname: Brown
mesh_terms: D015502:Absorptiometry, Photon; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D001857:Bone Matrix / Q000187:drug effects; D002113:Calcification, Physiologic / Q000187:drug effects; D006801:Humans; D010281:Parathyroid Hormone / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone
keywords: BMD; antiresorptive therapy; biochemical markers of bone turnover; bisphosphonates; denosumab; osteoanabolics; osteoporois; parathyroid hormone